Moderna's Personalized Cancer Vaccine Clears Phase 3, but Skeptics Ask Whether It Is Needed
Biotech·October 24, 2026
Merck and Moderna presented detailed Phase 3 results for intismeran autogene, an individualized mRNA cancer therapy, at the ESMO Congress on October 22. In the INTerpath-001 trial, patients with completely resected stage IIB to IV melanoma who received intismeran plus Keytruda (pembrolizumab) had a 42% lower risk of recurrence or death than patients given Keytruda alone. The two-year recurrence-free survival rate was 82.2%, compared with 70.0% for Keytruda alone. The companies say the results will be published in The New England Journal of Medicine.
The therapy is built around the unique mutations found in each patient's tumor, and it is given after surgery to lower the chance the cancer returns. Merck and Moderna call it the first Phase 3 study of this kind of individualized treatment to show a clinically meaningful benefit over Keytruda alone in adjuvant melanoma. The companies say they are now talking with regulators, but no approval has been granted.
The skeptics have specific concerns. The result on distant metastasis-free survival, which tracks whether cancer spreads to other parts of the body, was a 38% reduction in risk. That is well short of the roughly 65% reduction seen in the earlier Phase 2 trial, and analysts had hoped the Phase 3 would match it. The benefit also took time to appear. In the first six months, the vaccine combination performed about the same as Keytruda alone, and the stronger effect showed up only after the vaccine doses had been completed. Overall survival data are not yet mature enough to judge.
Safety looks broadly in line with earlier studies. Treatment-related adverse events were reported in 95.8% of patients on the combination, compared with 90.0% on Keytruda alone, and the companies say no new safety signals appeared. The most common side effects included fever, pain at the injection site and fatigue.
The bigger question is positioning. Keytruda is already approved as adjuvant therapy for some patients with resected stage IIB, IIC or III melanoma, so regulators and doctors will want to know how much the vaccine adds on top of that standard. A personalized product that must be made for each patient may face a higher bar than a conventional drug, both on clinical benefit and on cost and logistics. The answer will depend on the full data package, which has not yet been presented in a peer-reviewed journal.
Reporting based on an external source.